Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $7.00 at Piper Sandler

Karyopharm Therapeutics (NASDAQ:KPTI) had its price objective trimmed by Piper Sandler to $7.00 in a report released on Friday morning,Benzinga reports. The brokerage currently has an overweight rating on the stock.

Several other equities analysts have also recently issued reports on the company. HC Wainwright cut Karyopharm Therapeutics from a “buy” rating to a “negative” rating in a research note on Friday. Weiss Ratings downgraded Karyopharm Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday. Robert W. Baird lowered shares of Karyopharm Therapeutics from an “outperform” rating to a “neutral” rating and set a $3.00 target price on the stock. in a research note on Friday. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $16.00 target price on shares of Karyopharm Therapeutics in a report on Tuesday, July 21st. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a research note on Tuesday, June 9th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $11.50.

Karyopharm Therapeutics Trading Down 72.6%

Shares of NASDAQ KPTI opened at $1.92 on Friday. The stock has a market cap of $43.51 million, a P/E ratio of -0.13 and a beta of 0.80. The business’s fifty day simple moving average is $8.88 and its 200-day simple moving average is $8.19. Karyopharm Therapeutics has a 12-month low of $1.80 and a 12-month high of $10.99.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Thursday, May 14th. The company reported ($1.24) EPS for the quarter, topping the consensus estimate of ($1.45) by $0.21. The company had revenue of $35.07 million for the quarter, compared to analyst estimates of $31.40 million. On average, equities analysts forecast that Karyopharm Therapeutics will post -3.24 EPS for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Commodore Capital LP purchased a new stake in Karyopharm Therapeutics during the 1st quarter worth about $10,862,000. Context Capital Management LLC purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $464,000. Avidity Partners Management LP increased its holdings in shares of Karyopharm Therapeutics by 244.6% in the 1st quarter. Avidity Partners Management LP now owns 463,741 shares of the company’s stock valued at $2,583,000 after acquiring an additional 329,175 shares during the last quarter. Persistent Asset Partners Ltd purchased a new position in shares of Karyopharm Therapeutics in the 4th quarter valued at about $135,000. Finally, Tudor Investment Corp ET AL acquired a new stake in shares of Karyopharm Therapeutics during the 4th quarter worth about $95,000. 66.44% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Karyopharm Therapeutics

Here are the key news stories impacting Karyopharm Therapeutics this week:

• Positive Sentiment: Karyopharm plans to submit a supplemental New Drug Application in August 2026 seeking accelerated FDA approval for selinexor combined with ruxolitinib in myelofibrosis. The company will request priority review, and approval could make the treatment the first approved combination therapy in this setting. Karyopharm myelofibrosis sNDA announcement
• Positive Sentiment: Piper Sandler maintained an “overweight” rating while lowering its price target to $7.00. The target still indicates substantial potential upside if Karyopharm’s pipeline programs succeed.
• Neutral Sentiment: HC Wainwright reaffirmed its “neutral” rating but cut its price target to $3.00 from $13.00, reflecting sharply reduced expectations after the endometrial-cancer update.
• Neutral Sentiment: Robert W. Baird downgraded KPTI from “outperform” to “neutral” and set a $3.00 price target, signaling a more cautious view despite implied upside from recent trading levels.
• Neutral Sentiment: An executive vice president sold 189 shares for approximately $1,342, reducing the executive’s position by only 0.20%; the small transaction is unlikely to materially change the investment outlook. SEC insider transaction filing
• Negative Sentiment: Karyopharm’s Phase 3 XPORT-EC-042 trial failed to meet its primary progression-free-survival endpoint in endometrial cancer. Although median PFS favored selinexor by 5.3 months in the modified intent-to-treat population, the miss led the company to reduce investment in the program and refocus resources on myelofibrosis and multiple myeloma. Karyopharm XPORT-EC-042 trial results
• Negative Sentiment: Pomerantz LLP announced an investigation into potential claims on behalf of Karyopharm investors, adding legal overhang following the sharp decline. Pomerantz investor investigation

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.